Company intelligence / Profile preview
Molecular Templates, Inc.
Austin, Texas, USAmtem.com ↗
- Ownership
- Public · MTEM
- Employees
- ~62
- Development stage
- Other
01
Overview
Molecular Templates advanced several ETB-based biologic therapeutics into Phase 1 trials. Over 100 patients were treated across programs with promising safety and efficacy signals, including deep depletion of CD38+ immune cells in myeloma and anti-tumor activity in solid tumor settings. No capillary leak syndrome was observed—a common issue with similar immunotoxins—demonstrating a favorable safety profile. The company ceased operations before advancing to later-stage trials.
- Therapeutic areas
- Oncology
- Modalities
- Engineered Toxin Bodies (ETBs)Biologics
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Bristol Myers Squibb – collaboration to develop novel ETBs against multiple targets
Beyond the preview
Go deeper on Molecular Templates, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Molecular Templates, Inc..